Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 60/100

Diamond Equity Research Update Oct 2023 Valuation at 70 cents per share

Friday, October 20, 2023 1 min read
Key Takeaway: Radiopharm Theranostics has been highlighted in a recent update by Diamond Equity Research, which values the company at 70 cents per share. The update includes positive news regarding the company's clinical trials and FDA approvals. Notably, the company has initiated a Phase I study targeting B7H3 with its product BetaBart (RV-01).

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics has received IND approval from the US FDA.
  • The company is initiating a Phase I therapeutic clinical study.
  • Positive clinical updates have been provided across four programs.

Full Press Release Details

• Updates
• PDF
• October 20, 2023
Loading Viewer…

More Announcements & Updates

• Announcements
• March 15, 2024
• Announcements
• June 20, 2024
• Announcements
• January 10, 2022
• Announcements
• October 20, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the current valuation of Radiopharm Theranostics?

Diamond Equity Research values Radiopharm Theranostics at 70 cents per share.

What recent FDA approval did Radiopharm receive?

Radiopharm Theranostics received IND approval to initiate a Phase I study.

What is the focus of the Phase I study by Radiopharm?

The Phase I study targets B7H3 using the product BetaBart (RV-01).

How many clinical programs have positive updates?

Radiopharm has provided positive updates across four clinical programs.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics Phase I study B7H3 FDA approval
Last updated: Oct 20, 2023